These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 20529002)
1. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Marschner S; Fast LD; Baldwin WM; Slichter SJ; Goodrich RP Transfusion; 2010 Nov; 50(11):2489-98. PubMed ID: 20529002 [TBL] [Abstract][Full Text] [Related]
2. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Ambruso DR; Thurman G; Marschner S; Goodrich RP Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996 [TBL] [Abstract][Full Text] [Related]
3. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. Fast LD; DiLeone G; Cardarelli G; Li J; Goodrich R Transfusion; 2006 Sep; 46(9):1553-60. PubMed ID: 16965583 [TBL] [Abstract][Full Text] [Related]
4. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Fast LD; Nevola M; Tavares J; Reddy HL; Goodrich RP; Marschner S Transfusion; 2013 Feb; 53(2):373-81. PubMed ID: 22612327 [TBL] [Abstract][Full Text] [Related]
5. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989 [TBL] [Abstract][Full Text] [Related]
6. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Asano H; Lee CY; Fox-Talbot K; Koh CM; Erdinc MM; Marschner S; Keil S; Goodrich RP; Baldwin WM Transplantation; 2007 Nov; 84(9):1174-82. PubMed ID: 17998874 [TBL] [Abstract][Full Text] [Related]
7. Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products. Pohler P; Müller M; Winkler C; Schaudien D; Sewald K; Müller TH; Seltsam A Transfusion; 2015 Feb; 55(2):337-47. PubMed ID: 25134439 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990 [TBL] [Abstract][Full Text] [Related]
9. Pathogen-reduction systems for blood components: the current position and future trends. Seghatchian J; de Sousa G Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168 [TBL] [Abstract][Full Text] [Related]
10. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study. Picker SM; Steisel A; Gathof BS Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725 [TBL] [Abstract][Full Text] [Related]
11. Functional inactivation of white blood cells by Mirasol treatment. Fast LD; Dileone G; Li J; Goodrich R Transfusion; 2006 Apr; 46(4):642-8. PubMed ID: 16584442 [TBL] [Abstract][Full Text] [Related]
12. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Fast LD; DiLeone G; Marschner S Transfusion; 2011 Jul; 51(7):1397-404. PubMed ID: 21155832 [TBL] [Abstract][Full Text] [Related]
13. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812 [TBL] [Abstract][Full Text] [Related]
14. Study of CD69 antigen expression and integrity of leukocyte cellular membrane in stored platelet concentrates following irradiation and treatment with Mirasol® PRT System. Lachert E; Woźniak J; Antoniewicz-Papis J; Krzywdzińska A; Kubis J; Mikołowska A; Letowska M Adv Clin Exp Med; 2017; 26(1):7-13. PubMed ID: 28397426 [TBL] [Abstract][Full Text] [Related]
15. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Ostrowski SR; Bochsen L; Salado-Jimena JA; Ullum H; Reynaerts I; Goodrich RP; Johansson PI Transfusion; 2010 Oct; 50(10):2210-9. PubMed ID: 20456708 [TBL] [Abstract][Full Text] [Related]
16. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169 [TBL] [Abstract][Full Text] [Related]
17. Real-time measurement of platelet shape change by light scattering under riboflavin and ultraviolet light treatment. Terada C; Shiba M; Satake M; Tadokoro K Transfusion; 2016 Mar; 56(3):587-95. PubMed ID: 26536611 [TBL] [Abstract][Full Text] [Related]
18. Human platelets pathogen reduced with riboflavin and ultraviolet light do not cause acute lung injury in a two-event SCID mouse model. Chi X; Zhi L; Vostal JG Transfusion; 2014 Jan; 54(1):74-85. PubMed ID: 23656563 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. AuBuchon JP; Herschel L; Roger J; Taylor H; Whitley P; Li J; Edrich R; Goodrich RP Transfusion; 2005 Aug; 45(8):1335-41. PubMed ID: 16078923 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Tonnetti L; Proctor MC; Reddy HL; Goodrich RP; Leiby DA Transfusion; 2010 May; 50(5):1019-27. PubMed ID: 20030791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]